Zubair Shah, MD
Advanced Heart Failure and Transplant Cardiology · Kansas City, KSNPI 1386942126
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $276,627 of the $387,311 with a category attached, or 71.4%. Alnylam Pharmaceuticals Inc. accounts for 63.2% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $109,269, 6.2 times the $17,510 reported in 2019.
Across 716 payments — averaging $540.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$245K
- AstraZeneca$97K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29K
- Pfizer$6K
- Akcea Therapeutics, Inc.$4K
- Abbott$3K
- plus $3K from 23 others
Across 550 payments — averaging $3504.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$1.8M
- Abbott$92K
- Ionis Pharmaceuticals, Inc.$38K
- Procyrion, Inc.$32K
- AstraZeneca$10K
- Bayer$3K
What the payments were for
- Consulting fees$60,95216%
- Speaking & faculty fees$276,62771%
- Travel & lodging$32,4488%
- Food & beverage$17,1424%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 280 | $244,761 |
| AstraZeneca(2 entities) | 99 | $96,574 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $29,254 |
| Pfizer | 52 | $6,439 |
| Akcea Therapeutics, Inc. | 5 | $3,896 |
| Abbott | 55 | $2,891 |
| Impulse Dynamics (USA) Inc. | 16 | $638 |
| Abiomed | 3 | $458 |
| Merck | 23 | $374 |
| Novo Nordisk | 19 | $372 |
| Novartis | 16 | $264 |
| Bridgebio Pharma, Inc. | 4 | $226 |
| Cvrx, Inc. | 1 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $120 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $112 |
| Paragonix Technologies, Inc. | 2 | $110 |
| Boston Scientific | 1 | $97 |
| Amgen | 5 | $85 |
| Edwards Lifesciences | 3 | $84 |
| Boehringer Ingelheim | 5 | $81 |
| Daxor Corporation | 1 | $69 |
| Bayer | 3 | $57 |
| Ancora Heart, Inc. | 2 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$131,534
- ONPATTRO$98,544
- WAINUA$52,940
- LifeVest$26,781
- VYNDAQEL$5,686
- TEGSEDI$2,275
- HeartMate 3 Left Ventricular Dev$812
- OPTIMIZER$461
- Impella$458
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$282
- FARXIGA$187
- Xience Sierra Coronary Stent System$164
- Barostim Neo System$151
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$146
- Attruby$144
- CARDIOMEMS$124
- HeartMate 3 Left Ventricular Assist Device$119
- ONGLYZA$107
How this compares
Too few advanced heart failure and transplant cardiology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 958 | $21,073,188 |
| WainuaEplontersen Sodium | 35 | $1,372,360 |
| EntrestoSacubitril/Valsartan | 405 | $471,395 |
| JardianceEmpagliflozin | 337 | $398,076 |
| EliquisApixaban | 299 | $295,500 |
| FarxigaDapagliflozin Propanediol | 286 | $285,700 |
| OzempicSemaglutide | 111 | $108,935 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 18 | $74,502 |
| MounjaroTirzepatide | 59 | $59,403 |
| XareltoRivaroxaban | 44 | $53,781 |
| Repatha SureclickEvolocumab | 24 | $17,326 |
| CorlanorIvabradine Hcl | 11 | $13,611 |
| Bumetanide | 246 | $11,732 |
| Mycophenolic AcidMycophenolate Sodium | 24 | $7,908 |
| Tacrolimus | 37 | $6,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $6,439 | $21,368,6881,257 claims |
| AstraZenecaWainua, Farxiga | $96,574 | $1,658,060321 claims |
| NovartisEntresto, Sandostatin Lar Depot | $264 | $545,897423 claims |
| Boehringer IngelheimJardiance | $81 | $398,076337 claims |
| Novo NordiskOzempic | $372 | $108,935111 claims |
| AmgenCorlanor | $85 | $13,61111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kansason file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Kansas City
- Hirak ShahKansas City$29K
- Pradeep MammenKansas City$18K
- Tarun DaliaKansas City$16K
- Michelle DimzaKansas City$12K
- Raja ZaghlolKansas City$5K
- Mohamed El KhashabKansas City$4K
- Jane TitteringtonKansas City$4K
- Paola RoldanKansas City$3K
- Daniel HarrisonKansas City$1K
- Deepthi VodnalaOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.